<*dv_5*>Endocardial Solutions Sells Approximately $7.3 Millionin Common Stock and Repays Loan to Medtronic

March 22, 2001

MINNEAPOLIS / ST.PAUL -- Endocardial Solutions, Inc. (Nasdaq: ECSI) today announced the sale of approximately $7.3 million of common stock in a private placement of 2,449,000 shares of the Company to institutional investors through US Bancorp Piper Jaffray, as agent. The closing of the sale is expected to occur on Monday, March 26. The Company also announced the repayment of a $7 million loan to Medtronic, Inc. (NYSE:MDT).

<*dv_3*>"This financing will move us closer to our goal of profitability," said Jim Bullock, President and Chief Executive Officer. "Our business model continues to mature and thus is more predictable in both the timing of our EnSite® system sales and EnSite® catheter utilization. The investment we made last year to expand our sales and clinical engineering team is paying significant dividends. Mike Dale, Vice President of Sales and Marketing has his team focused and prepared to meet the objectives for this year," said Bullock.

<*dv_0*>The U.S. Food and Drug Administration cleared the EnSite 3000® System for use in diagnostic mapping of complex arrhythmias in the right atrium of the heart during the second quarter 1999. Through a distribution agreement with Medtronic, Inc. (www.medtronic.com), the EnSite 3000® System and catheter have been available to electrophysiologists in Europe since the second quarter 1998.

Based in St. Paul, Minnesota, Endocardial Solutions (www.endocardial.com) develops, manufactures and markets technology for diagnostic mapping of complex arrhythmias (abnormally rapid heartbeats caused by irregular electrical activity in the heart).

<*dv_4*>The discussion above is based on preliminary financial results, which are subject to further review and adjustment, and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding gross margins, operating expenses and revenue expectations, that involve a number of risks and uncertainties. A number of factors should be considered in conjunction with these forward-looking statements. These factors are set forth in the cautionary statements included in Exhibit 99 to Endocardial Solutions' Form 10-Q for the quarter ended September 30, 2000, filed with the Securities and Exchange Commission. Endocardial Solutions cautions investors and others to review the statements set forth in that report and that other factors may prove to be important in affecting the business and results of operations of Endocardial Solutions.

Contacts:

Jim Bullock, President and CEO, Endocardial Solutions (651) 523-6928, jbullock@endocardial.com